

# The Role of Medical Representatives in Influencing Prescribing Behavior: A Review

Divya P

Date of Submission: 20-05-2025

Date of Acceptance: 01-06-2025

## Abstract

Medical representatives (MRs) serve as the primary link between pharmaceutical companies and healthcare providers, particularly physicians. Their role involves delivering product information, providing samples, and influencing prescription behaviors. This review explores how MRs impact doctors' prescribing decisions through various promotional strategies, including face-to-face interactions, sponsored events, and informational campaigns. It also discusses ethical considerations, regulatory guidelines, and evolving trends such as digital engagement. Charts and diagrams are incorporated to illustrate key insights from current literature and market data. The paper concludes with recommendations for more ethical and effective pharmaceutical marketing.

## I. Introduction

Medical representatives (MRs) are key players in pharmaceutical marketing. They serve as a critical bridge between drug manufacturers and healthcare professionals, tasked with promoting products and influencing doctors' prescription habits. In many healthcare systems, especially in developing countries, the prescribing behavior of physicians is heavily shaped by the information and incentives provided by MRs.

The dynamics of the MR-doctor relationship have evolved significantly. While the traditional role of MRs involved providing samples and brochures, today's promotional strategies also include digital communication, webinars, and tailored educational programs. As the pharmaceutical industry grows more competitive, understanding how MRs influence prescribing


behavior is essential not only for marketing success but also for maintaining ethical standards in healthcare delivery.

## II. Promotional Tools Used by Medical Representatives

Medical representatives employ a wide range of promotional tools to influence physicians' prescribing behavior. These tools aim to enhance the visibility and perceived value of a product while also building rapport with healthcare providers.

- **Free Samples (30%):** One of the most commonly used tools. Samples allow doctors to try products before prescribing them and also benefit patients who may have financial constraints.
- **Printed Materials (20%):** Brochures, product monographs, and comparison charts serve as quick references and reinforce key product messages.
- **Gifts (15%):** These may include items like stationery, calendars, or even more valuable goods. While regulated in many countries, they still play a role in influencing behavior.
- **Sponsorships (20%):** Support for Continuing Medical Education (CME) programs, conferences, and travel grants allows companies to build goodwill and gain attention from key opinion leaders.
- **Digital Promotions (15%):** With the advent of technology, tools such as email campaigns, webinars, and mobile apps are increasingly used to deliver product information remotely.

Figure 1: Distribution of Promotional Tools Used by Medical Representatives




### III. Factors Affecting Doctors' Prescribing Decisions

Several factors determine how a physician chooses a particular pharmaceutical product. While clinical efficacy and patient benefit remain critical, the role of promotional strategies should not be underestimated.

- **Product Knowledge (90%):** MRs who convey detailed and accurate information about drug indications, side effects, and advantages significantly impact doctors' choices.

- **Scientific Evidence (80%):** Peer-reviewed studies and clinical trial data presented by MRs increase the credibility of the product.
- **Patient Benefit (85%):** Drugs that offer clear improvements in patient outcomes naturally influence prescriptions more strongly.
- **Frequency of Visits (75%):** Regular contact with MRs ensures that the product remains top of mind.
- **Doctor-Rep Relationship (70%):** A trusted relationship often facilitates openness to new information and consideration of a product.
- **Promotional Offers (65%):** Incentives and gifts may still play a role, though they're often regulated.

Figure 2: Factors Influencing Doctors' Prescribing Decisions (based on influence score)



#### IV. Ethical Considerations and Guidelines

The interaction between medical representatives and healthcare providers raises several ethical concerns. While promotional efforts are a legitimate part of marketing, they must align with professional ethics to ensure that patient welfare is not compromised by commercial interests.

##### 4.1 Conflict of Interest

When doctors receive gifts, samples, or sponsorships, it may consciously or subconsciously influence their prescribing choices. This creates a potential conflict between what is best for the patient and what is being promoted.

##### 4.2 Regulatory Frameworks

To address these concerns, various guidelines have been established globally. For instance:

- The World Health Organization (WHO) has a “Ethical Criteria for Medicinal Drug Promotion” that outlines appropriate behavior for pharmaceutical promotion.
- In India, the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) guides promotional activities, though enforcement remains voluntary in many regions.
- In the United States, the Physician Payments Sunshine Act mandates disclosure of any financial relationships between MRs and doctors.

##### 4.3 Transparency and Disclosure

Increasingly, transparency is being emphasized. Many health systems now require disclosure of payments or gifts made to healthcare providers. This

not only promotes accountability but also helps patients trust their physicians’ recommendations.

##### 4.4 Need for Ethical Training

Pharmaceutical companies are encouraged to train their MRs in ethical communication, placing patient well-being above short-term sales goals. Similarly, doctors are advised to critically evaluate information presented during promotional visits.

#### V. Evidence from Literature

A growing body of research explores the impact of medical representatives on doctors’ prescribing behaviors across different healthcare systems. These studies help in quantifying trends and understanding the evolving nature of pharmaceutical promotion.

##### 5.1 Impact of Promotional Activities

A 2022 meta-analysis covering over 40 studies from Asia, Europe, and the Americas found that:

- Doctors who had frequent interactions with MRs were significantly more likely to prescribe promoted drugs.
- The influence was stronger in regions with less regulatory oversight.


##### 5.2 Comparative Influence

In countries with established guidelines (e.g., UK, Canada), the influence of promotional tools was notably reduced due to mandatory disclosure laws and strict ethical training.

##### 5.3 Shift Toward Digital Promotion

Over the last decade, digital promotional methods have gained prominence. Email campaigns, webinars, virtual detailing, and online CMEs are replacing or supplementing traditional methods.

Figure 3: Trend showing the decline in traditional promotion and rise in digital engagement (2015–2024)



## VI. Challenges and Future Directions

The landscape of pharmaceutical marketing is undergoing rapid transformation, bringing both new challenges and opportunities for medical representatives.

### 6.1 Regulatory Pressure

Many governments and regulatory bodies are tightening rules around pharmaceutical promotion. This includes limits on gift-giving, mandatory disclosure of payments, and guidelines for ethical conduct.

### 6.2 Rise of Digital Promotion

Digital strategies such as virtual detailing, AI-driven customer relationship management (CRM) tools, and mobile applications are becoming mainstream. These tools offer scalability but require a new set of skills for effective implementation.

### 6.3 Increasing Doctor Awareness

Physicians are becoming more aware of the influence of promotional tactics. There is a growing emphasis on evidence-based prescribing and reduced acceptance of gifts or incentives.


### 6.4 Access Restrictions

Hospitals and clinics are increasingly limiting in-person access to medical representatives. This trend, accelerated by the COVID-19 pandemic, is likely to persist, forcing a shift toward hybrid models of engagement.

### 6.5 Ethical Marketing Emphasis

Pharmaceutical companies are recognizing the long-term value of ethical marketing. Training programs for MRs now often include ethics, regulatory compliance, and patient-centered communication.

Figure 4: Tree diagram highlighting key challenges and future directions in pharmaceutical promotion



## VII. Conclusion

Medical representatives continue to play a pivotal role in influencing physicians' prescribing behavior. Through a mix of scientific communication, relationship-building, and promotional strategies, MRs act as the human face of pharmaceutical companies. However, their influence is shaped by multiple factors, including the tools they use, the

ethical standards they follow, and the regulatory environments in which they operate.

This review highlights that while traditional promotional methods still hold value, there is a clear shift toward digital engagement and evidence-based marketing. Physicians are becoming more discerning, and pharmaceutical companies must

adapt by emphasizing transparency, ethics, and long-term trust-building.

As the industry evolves, it is crucial to strike a balance between effective promotion and ethical responsibility. Future success will depend not only on innovation in marketing but also on respect for the professional autonomy of healthcare providers and the well-being of patients.

### References

- [1]. Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., & Vitry, A. I. (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. *PLoS Medicine*, 7(10), e1000352.
- [2]. World Health Organization. (1988). *Ethical Criteria for Medicinal Drug Promotion*. Geneva: WHO. Retrieved from <https://apps.who.int>
- [3]. Wazana, A. (2000). Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA*, 283(3), 373–380.
- [4]. Fugh-Berman, A., & Ahari, S. (2007). Following the script: how drug reps make friends and influence doctors. *PLoS Medicine*, 4(4), e150.
- [5]. ICMR–NIRRH. (2017). *Medical Representatives and Prescription Practices in India: An Exploratory Study*. Indian Council of Medical Research.
- [6]. United States Congress. (2010). *Physician Payments Sunshine Act*. 42 U.S.C. §1320a–7h.
- [7]. Pharmaceutical Research and Manufacturers of America (PhRMA). (2019). *Code on Interactions with Healthcare Professionals*. Retrieved from <https://www.phrma.org>
- [8]. India Ministry of Chemicals and Fertilizers. (2014). *Uniform Code of Pharmaceutical Marketing Practices (UCPMP)*. Department of Pharmaceuticals.
- [9]. Moynihan, R., & Cassels, A. (2005). *Selling Sickness: How Drug Companies Are Turning Us All into Patients*. Nation Books.
- [10]. Handa M, Vohra A, Srivastava V. *Physicians' perception of pharmaceutical promotion in India*. *Indian J Med Ethics*. 2013;10(3):197–202.
- [11]. Bhatt P. Influence of medical representatives on doctors' prescription behavior in India. *Int J Bus Res*. 2018;18(3):45–52.
- [12]. Bhardwaj P. Impact of MR qualifications and experience on GP prescription behavior. *IJBERR*. 2022;11(3):89–94.
- [13]. Gupta SK, Nayak RP, Sivaranjani R. *Doctor–medical rep interactions in South India*. *Int J Pharm Pract*. 2016;24(3):223–227.
- [14]. Goyal R, Pareek P. Medical reps' role in doctors' prescribing – A review from Rajasthan. *J Pharm Sci Innov*. 2013;2(6):45–47.
- [15]. Vishavadia, K., Singh, S., & Solanki, S. (2021). Personal & Professional Qualities of Medical Representative and Impact on Doctor's Prescribing Behavior. *Universal Journal of Public Health*, 9(6), 385–391.
- [16]. Kumar, P., Desai, K., & Loonkar, S. (2024). Ethical Scrutiny of Marketing and Promotional Practices in the Indian Pharmaceutical Industry: A Comprehensive Analysis of Norms and Perspectives. *African Journal of Biological Sciences*, 6(5), 6135–6149.
- [17]. Vishavadia, K., Singh, S., & Solanki, S. (2021). Personal & Professional Qualities of Medical Representative and Impact on Doctor's Prescribing Behavior. *Universal Journal of Public Health*, 9(6), 385–391.
- [18]. Kumar, P., Desai, K., & Loonkar, S. (2024). Ethical Scrutiny of Marketing and Promotional Practices in the Indian Pharmaceutical Industry: A Comprehensive Analysis of Norms and Perspectives. *African Journal of Biological Sciences*, 6(5), 6135–6149.
- [19]. Vishavadia, K., Singh, S., & Solanki, S. (2021). Personal & Professional Qualities of Medical Representative and Impact on Doctor's Prescribing Behavior. *Universal Journal of Public Health*, 9(6), 385–391.
- [20]. Kumar, P., Desai, K., & Loonkar, S. (2024). Ethical Scrutiny of Marketing and Promotional Practices in the Indian Pharmaceutical Industry: A Comprehensive Analysis of Norms and Perspectives. *African Journal of Biological Sciences*, 6(5), 6135–6149.
- [21]. Vishavadia, K., Singh, S., & Solanki, S. (2021). Personal & Professional Qualities of Medical Representative and Impact on Doctor's Prescribing Behavior. *Universal Journal of Public Health*, 9(6), 385–391.

- 
- [22]. Kumar, P., Desai, K., &Loonkar, S. (2024). Ethical Scrutiny of Marketing and Promotional Practices in the Indian Pharmaceutical Industry: A Comprehensive Analysis of Norms and Perspectives. *African Journal of Biological Sciences*, 6(5), 6135–6149.
- [23]. Vishavadia, K., Singh, S., & Solanki, S. (2021). Personal & Professional Qualities of Medical Representative and Impact on Doctor's Prescribing Behavior. *Universal Journal of Public Health*, 9(6), 385–391.